MedTrace Logo

Efficacy Study of IgY (Antibody Against Pseudomonas) in Cystic Fibrosis Patients

NCT01455675 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2017-07-06

No results posted yet for this study

Summary

The purpose of this study is to prolong the time to reinfection with Pseudomonas aeruginosa after successfully treated acute or intermittent infection.

Conditions

Interventions

DRUG

IgY

Avian polyclonal anti-pseudomonas antibodies (IgY)

DRUG

Placebo

Placebo, 70 ml gargling solution, once daily

Sponsors & Collaborators

  • Mukoviszidose Institut gGmbH

    lead OTHER

Principal Investigators

  • Antje Schuster, Prof. Dr. · University Düsseldorf

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2017-06-27
Completion
2017-06-27

Countries

  • Austria
  • Belgium
  • Germany
  • Hungary
  • Ireland
  • Italy
  • Poland
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455675 on ClinicalTrials.gov